Adverse cardiovascular events morbidity and mortality, and HIV exposure in cardiovascular disease patients in Northern Uganda
Journal of Kenya Assocation of Physicians · 2024
DOI: 10.4314/jkap.v6i2.22a ↗Abstract
Background: Cardiovascular Disease (CVD) morbidity and mortality persist globally, even among patients living with Human Immunodeficiency Virus (HIV) infection in sub-Saharan Africa.Objective: We aimed to determine the risk of all-cause mortality and morbidity of Major Adverse Cardiovascular Events (MACE) components (stroke, Acute Myocardial Infarction (AMI), and heart failure), comparing CVD patients with and without HIV infection hospitalized in two hospitals in northern Uganda.Methods: We conducted a retrospective cohort study at Lira Regional Referral Hospital (LRRH) and Lira University Hospital (LUH) in northern Uganda. We compared outcomes between HIV and non-HIV CVD patients hospitalized from January 1st, 2015, to January 2022. Using logistic regression, Kaplan Meier, and Cox proportional hazards models, we conducted crude, adjusted, and stratified analyses for the association between components of MACE, and mortality by HIV status adjusting for confounders, and further stratified by HIV status.Results: We identified 2,127 CVD patients, 292 (13.7%) were HIV positive, and 1,835 were non-HIV CVD patients. The majority were female (60.5%), and the HIV-positive group was younger (median age = 51 years) than the non-HIV group (median = 65 years). The risk of all-cause mortality during hospitalization was 26% and 15.8% among HIV-CVD and non-HIV CVD patients respectively. Cardiac patients with HIV had a higher proportion of heart failure (38.1% vs. 22.9%), AMI (60% vs. 36.5%), and stroke (41.8% vs. 27.8%) compared to non-HIV CVD patients. Despite the high risk of MACE among HIV-CVD patients, mortality risks remain comparable to non-HIV CVD patients. The risk of death among CVD patients with HIV-positive includes; heart failure (OR: 3.06, 95% CI: [1.56, 6.32], p-value = 0.002), stroke (OR: 2.50, 95% CI: [1.15, 5.42], p-value = 0.020), AMI (OR: 9.29, 95% CI: [4.64,19.34], p-value
EUVIMED